Lanreotide (Somatuline Depot)
Overview
A synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. Lanreotide is formulated as a supersaturated solution that forms a drug depot at the injection site, providing sustained release over 4 weeks.
Mechanism of Action
It inhibits GH secretion, GI hormone release, and has direct antiproliferative effects on neuroendocrine tumor cells through cell cycle arrest and apoptosis induction.
Research Summary & Key Findings
FDA-approved for acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). CLARINET trial demonstrated significant antiproliferative effect in nonfunctioning GEP-NETs with median PFS not reached vs. 18 months for placebo (Caplin et al., NEJM, 2014). Deep subcutaneous injection by patient or caregiver allows home administration. Comparable efficacy to octreotide LAR with improved convenience.
Clinical Status
Lanreotide (Somatuline Depot) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Lanreotide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Lanreotide"
Registered interventional and observational studies, including status and phase.
- PubChem — "Lanreotide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Gastrointestinal
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneou...
View detailsPasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly...
View detailsPlecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates f...
View detailsLinaclotide (Linzess)
FDA ApprovedA synthetic 14-amino acid peptide structurally related to the heat-stable enterotoxin of Escherichia coli and the endoge...
View detailsStart Your Consultation
Get an AI-proposed Lanreotide (Somatuline Depot) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Lanreotide (Somatuline Depot).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.